Observational studyThe oncologist2022

First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study.

Martina Lorenzi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.